PDF(Pubmed)
Abstract：
UNASSIGNED: Small nuclear ribonucleoprotein U1 subunit 70 (SNRNP70) as one of the components of the U1 small nuclear ribonucleoprotein (snRNP) is rarely reported in cancers. This study aims to estimate the application potential of SNRNP70 in hepatocellular carcinoma (HCC) clinical practice.
UNASSIGNED: Based on the TCGA database and cohort of HCC patients, we investigated the expression patterns and prognostic value of SNRNP70 in HCC. Then, the combination of SNRNP70 and alpha-fetoprotein (AFP) in 278 HCC cases was analyzed. Next, western blotting and immunohistochemistry were used to detect the expression of SNRNP70 in nucleus and cytoplasm. Finally, Cell Counting Kit-8 (CCK-8) and scratch wound healing assays were used to detect the effect of SNRNP70 on the proliferation and migration of HCC cells.
UNASSIGNED: SNRNP70 was highly expressed in HCC. Its expression was increasingly high during the progression of HCC and was positively related to immune infiltration cells. Higher SNRNP70 expression indicated a poor outcome of HCC patients. In addition, nuclear SNRNP70/AFP combination could be a prognostic biomarker for overall survival and recurrence. Cell experiments confirmed that knockdown of SNRNP70 inhibited the proliferation and migration of HCC cells.
UNASSIGNED: SNRNP70 may be a new biomarker for HCC progression and HCC diagnosis as well as prognosis. SNRNP70 combined with serum AFP may indicate the prognosis and recurrence status of HCC patients after operation.
UNASSIGNED: Based on the TCGA database and cohort of HCC patients, we investigated the expression patterns and prognostic value of SNRNP70 in HCC. Then, the combination of SNRNP70 and alpha-fetoprotein (AFP) in 278 HCC cases was analyzed. Next, western blotting and immunohistochemistry were used to detect the expression of SNRNP70 in nucleus and cytoplasm. Finally, Cell Counting Kit-8 (CCK-8) and scratch wound healing assays were used to detect the effect of SNRNP70 on the proliferation and migration of HCC cells.
UNASSIGNED: SNRNP70 was highly expressed in HCC. Its expression was increasingly high during the progression of HCC and was positively related to immune infiltration cells. Higher SNRNP70 expression indicated a poor outcome of HCC patients. In addition, nuclear SNRNP70/AFP combination could be a prognostic biomarker for overall survival and recurrence. Cell experiments confirmed that knockdown of SNRNP70 inhibited the proliferation and migration of HCC cells.
UNASSIGNED: SNRNP70 may be a new biomarker for HCC progression and HCC diagnosis as well as prognosis. SNRNP70 combined with serum AFP may indicate the prognosis and recurrence status of HCC patients after operation.
摘要：
■在癌症中很少报道小核核糖核蛋白U1亚基70（SNRNP70）作为U1小核核糖核蛋白（snRNP）的组成部分之一。本研究旨在评估SNRNP70在肝细胞癌（HCC）临床实践中的应用潜力。
■基于TCGA数据库和HCC患者队列，我们研究了SNRNP70在HCC中的表达模式和预后价值。然后，分析了278例HCC病例中SNRNP70和甲胎蛋白（AFP）的组合。接下来,免疫印迹法和免疫组化法检测SNRNP70在细胞核和细胞质中的表达。最后,细胞计数试剂盒-8(CCK-8)和划痕伤口愈合试验用于检测SNRNP70对HCC细胞增殖和迁移的影响。
■SNRNP70在HCC中高表达。其表达在肝癌进展过程中日益增高，并与免疫浸润细胞呈正相关。较高的SNRNP70表达表明HCC患者的预后较差。此外,核SNRNP70/AFP组合可能是总体生存和复发的预后生物标志物。细胞实验证实，敲低SNRNP70抑制HCC细胞的增殖和迁移。
■SNRNP70可能是HCC进展和HCC诊断以及预后的新生物标志物。SNRNP70联合血清AFP可提示HCC患者的预后及术后复发情况。
■基于TCGA数据库和HCC患者队列，我们研究了SNRNP70在HCC中的表达模式和预后价值。然后，分析了278例HCC病例中SNRNP70和甲胎蛋白（AFP）的组合。接下来,免疫印迹法和免疫组化法检测SNRNP70在细胞核和细胞质中的表达。最后,细胞计数试剂盒-8(CCK-8)和划痕伤口愈合试验用于检测SNRNP70对HCC细胞增殖和迁移的影响。
■SNRNP70在HCC中高表达。其表达在肝癌进展过程中日益增高，并与免疫浸润细胞呈正相关。较高的SNRNP70表达表明HCC患者的预后较差。此外,核SNRNP70/AFP组合可能是总体生存和复发的预后生物标志物。细胞实验证实，敲低SNRNP70抑制HCC细胞的增殖和迁移。
■SNRNP70可能是HCC进展和HCC诊断以及预后的新生物标志物。SNRNP70联合血清AFP可提示HCC患者的预后及术后复发情况。
